Dr. Iravani is a nuclear medicine physician at the Mallinckrodt Institute of Radiology, Washington University School of Medicine in St Louis, leading the clinical Theranostic Nuclear Medicine program. Before his current role, he worked at the Center for Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Center (PMCC), Melbourne, Australia. He finished training in Nuclear Medicine and Internal Medicine and became a fellow of the Royal College of Physicians in Australia. Dr. Iravani’s fellowship was in Molecular Imaging and Radiopharmaceutical Therapy at PMCC. Dr. Iravani has been actively involved in the multiple practice-changing theranostic clinical trials and contributed to multiple seminal publications in this field. He is currently a member of multiple national committees in theranostics including the board of directors of SNMMI Theranostic Center of Excellence and the PRRT dosimetry working group at the National Cancer Institute.
Dr. Iravani has a broad interest in molecular imaging and therapeutic nuclear medicine applications in a variety of tumors including neuroendocrine tumors, prostate cancer, and thyroid cancer. His clinical practice and research’s focus is on the characterization of tumor biology by molecular imaging with the emphasis on the patient selection for the most appropriate treatment, therapeutic monitoring, and identifying the factors medicating the therapeutic success or resistance. His scope of practice and research also expands to radiopharmaceutical therapy whereby highly targeted systemic radiotherapy is delivered to the cancer tissues utilizing the biological targets specific to tumors.
Disclosures:
- Employment: none
- Compensation: none
- Ownership: none
- Leadership: none